Overview

Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam

Status:
Completed
Trial end date:
2018-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the abuse potential of CBD to determine whether it should remain as a Schedule I drug under the Controlled Substances Act, or be recommended for decontrol.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute on Drug Abuse (NIDA)
Treatments:
Alprazolam
Dronabinol